Protalix BioTherapeutics (PLX) Smacked On UBS Intra-Day Downgrade
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $1.18 -2.48%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Join SI Premium – FREE
An intra-day downgrade pushed shares of Protalix BioTherapeutics, Inc. (NYSE: PLX) down over 5%, although the stocks is now recovering into the close - currently down 3%.
UBS downgraded shares from Buy to Neutral and cut their price target from $11 to $10. Analyst Christopher Schaefer said, "we believe upside from current levels is limited based on fundamentals." The current price reflects the approval, he stated.
Although UBS still expects FDA approval by the Feb 25th PDUFA date, the firm has re-examined their Gaucher disease market assumptions. UBS now forecast 2015E taliglucerase alfa revenues of $52.3m in the US, $208.6m ROW (excluding Israel) and $45.7m in Israel.
In addition to U.S. approval, UBS expects Israeli approval shortly after and EU and Brazilian approval in 3Q11.
UBS mentioned a draft version of the taliglucerase label was posted on the Brazilian Ministry of Health website, which contains a black box warning and it further characterized the hypersensitivity reactions observed in the pivotal trial as anaphylactoid reactions. "According to PLX, this was an old version used for the expanded access program and its current regulatory submissions contain a different version that is very similar to Cerezyme's. If a black box is included in the final label, we see downside risk to the shares," Schaefer notes.
UBS downgraded shares from Buy to Neutral and cut their price target from $11 to $10. Analyst Christopher Schaefer said, "we believe upside from current levels is limited based on fundamentals." The current price reflects the approval, he stated.
Although UBS still expects FDA approval by the Feb 25th PDUFA date, the firm has re-examined their Gaucher disease market assumptions. UBS now forecast 2015E taliglucerase alfa revenues of $52.3m in the US, $208.6m ROW (excluding Israel) and $45.7m in Israel.
In addition to U.S. approval, UBS expects Israeli approval shortly after and EU and Brazilian approval in 3Q11.
UBS mentioned a draft version of the taliglucerase label was posted on the Brazilian Ministry of Health website, which contains a black box warning and it further characterized the hypersensitivity reactions observed in the pivotal trial as anaphylactoid reactions. "According to PLX, this was an old version used for the expanded access program and its current regulatory submissions contain a different version that is very similar to Cerezyme's. If a black box is included in the final label, we see downside risk to the shares," Schaefer notes.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Downgrades Li Auto (LI) to Equalweight
- RBC Capital Downgrades Range Resources (RRC) to Sector Perform
- Stifel Downgrades Knight Transportation (KNX) to Hold
Create E-mail Alert Related Categories
Downgrades, Hot Downgrades, Insiders' BlogRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
